Goldman Sachs
HSCS icon

Goldman Sachs’s Heart Test Laboratories HSCS Stock Holding History

Goldman Sachs’s Portfolio HSCS Stock Details HSCS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-458
Closed -$5.36K – 5763
2024
Q1 		$5.36K Buy
+458
New +$5.99K ﹤0.01% 5451

Other funds holding HSCS

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
CC
Cultivar Capital Denton, Texas $155M AUM 16.34% 1-Year Est. Return
OLVIG
Oliver Lagore Vanvalin Investment Group Flint, Michigan $255M AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs's HSCS Position: Q2 2024 in Review

Goldman Sachs sold out of Heart Test Laboratories (HSCS) in Q2 2024, closing a stake of 458 shares — an estimated $5.36K sold.

Goldman Sachs first reported a position in HSCS in Q1 2024 and held it in 1 quarter. The position peaked at $5.36K in Q1 2024. 7 funds tracked by Wall St. Rank hold HSCS as of Q2 2024.

  • Goldman Sachs reported no remaining Heart Test Laboratories position as of Q2 2024 after selling out during the quarter.
  • Goldman Sachs sold 458 Heart Test Laboratories shares in Q2 2024, an estimated $5.36K.
  • Goldman Sachs first reported a position in Heart Test Laboratories in Q1 2024 and held it in 1 quarter.
  • Goldman Sachs's Heart Test Laboratories position peaked at $5.36K in Q1 2024.
  • 7 funds tracked by Wall St. Rank held Heart Test Laboratories as of Q2 2024.

Based on Goldman Sachs's 13F filing for Q2 2024, filed 13 Aug 2024.